TRODELVY 200 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION

USDailyMed:Sacituzumab govitecan AU:DContraindicated L01FX17(WHO) AU:S4(Prescription only)CA:℞-only/Schedule DUS:℞-onlyEU:Rx-only 1491917-83-9 91668186 DB12893 none M9BYU8XDQ6 D10985 ChEMBL3545262 DTXSID401335985 Interactive image CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)OC(=O)OCC5=CC=C(C=C5)NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN6C=C(N=N6)CNC(=O)C7CCC(CC7)CN8C(=O)CC(C8=O)SCC(C(=O)O)N)C2=NC9=C1C=C(C=C9)O InChI=1S/C76H104N12O24S/c1-3-55-56-37-54(89)16-17-61(56)83-68-57(55)43-87-63(68)38-59-58(71(87)95)45-110-74(99)76(59,4-2)112-75(100)111-44-50-10-14-52(15-11-50)81-70(94)62(7-5-6-18-77)82-66(91)47-109-46-65(90)79-19-21-101-23-25-103-27-29-105-31-33-107-35-36-108-34-32-106-30-28-104-26-24-102-22-20-86-42-53(84-85-86)40-80-69(93)51-12-8-49(9-13-51)41-88-67(92)39-64(72(88)96)113-48-60(78)73(97)98/h10-11,14-17,37-38,42,49,51,60,62,64,89H,3-9,12-13,18-36,39-41,43-48,77-78H2,1-2H3,(H,79,90)(H,80,93)(H,81,94)(H,82,91)(H,97,98)/t49?,51?,60-,62-,64?,76-/m0/s1Key:ULRUOUDIQPERIJ-PQURJYPBSA-N Sacituzumab govitecan, sold under the brand nameTrodelvybyGilead Sciences, is aTrop-2-directedantibodyandtopoisomerase inhibitordrug conjugate used for the treatment ofmetastatictriple-negative breast cancer, previously treated metastatic hormone receptor–positive, HER2-negative breast cancer, and metastatic urothelial cancer. The most common side effects includenausea,neutropenia,diarrhea,fatigue,anemia,vomiting,alopecia(hair loss),constipation,decreased appetite,rashandabdominal pain.Sacituzumab govitecan has a boxed warning about the risk of severeneutropenia(abnormally low levels of white blood cells) and severe diarrhea.Sacituzumab govitecan may cause harm to a developing fetus or newborn baby. Sacituzumab govitecan was approved for medical use in the United States in April 2020,and in the European Union in November 2021.The U.S.Food and Drug Administration(FDA) and theEuropean Medicines Agency(EMA) consider it to be afirst-in-class medication.